DYNAVAX INITIATES PHASE 3 TRIAL FOR HEPATITIS B VACCINE.
Biotech Business › Vol. 18 Nbr. 8, August 2005
Linked as:
Extract
DYNAVAX INITIATES PHASE 3 TRIAL FOR HEPATITIS B VACCINE.
Dynavax Technologies Corporation (Nasdaq: DVAX), Berkeley, Calif., has initiated a pivotal Phase 3 clinical trial of its hepatitis B (HBV) vaccine. The pivotal Phase 3 trial is designed to compare the effectiveness of Dynavax's HBV vaccine to GlaxoSmithKline's Engerix-B(R) HBV vaccine in an older adult population that is more difficult ...
See the full content of this document
Sponsored links
